New Synthesis of ‘FMCA’: A potential Anti-HBV Drug Candidate

FMCA

A new and potent anti-HBV drug candidate has been discovered by our research group here at Drug Discovery Group (College of Pharmacy, Department of Pharmaceutical and Biomedical Sciences) of the University of Georgia.   FMCA stands for Fluoro and Methylene substituted derivative of Carbocyclic Adenosine. It has a 2’-F substitution and 6’ exocyclic methylene group which distinguishes it from Aristeromycin, […]

» Read more

The New Hep C Drug: PSI-7977 to Sofosbuvir

Recently (December 6th, 2013) Sofosbuvir was approved by US FDA for the treatment of Chronic Hepatitis C in combination with Ribavirin for dual therapy and with Ribavirin & Pegylated Interferon triple therapy for treatment-naive patients having HCV genotypes 1 and 4. The drug is being marketed as Sovaldi by Gilead.

» Read more

Design & Development of Unnatural Nucleosides as Antiviral & Anti-Cancer Agents

Design & Development of Unnatural Nucleosides as Antiviral & Anti-Cancer Agents   Ram C. Mishra   College of Pharmacy, University of Georgia, GA 30602, USA  Unnatural nucleosides are the variants (chemically modified analogs) of five natural nucleosides which constitute the structure of DNA and RNA. Since the first preparation and later, the isolation of unnatural nucleosides from plants; nucleoside chemistry […]

» Read more
1 2 3